Trial Profile
A randomized phase 3, double-blind, placebo-controlled study of the efficacy and safety of lonidamine for the treatment of symptomatic benign prostatic hyperplasia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lonidamine (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 19 Oct 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004110).
- 08 Nov 2005 New trial record.